A paradigm shift? Game changer? Both Hayes and Markus acknowledge how lofty their words must sound, especially without a finished device yet revealed to the public. But Hayes carries himself like a player who knows he has a winning hand, he just needs to wait his turn. “I realize the Fortune 500 companies like Medtronic or St. Jude will look at us and scoff like we're another newcomer trying to thump their chest,” Hayes says. “And to some extent they're right because we're a pittance compared to them currently financially. But we have technology that we know they would love to have and that's what makes us something meaningful and something to recon with in the future.”
Confidence certainly, but as any experienced player will tell you only time will tell whether EPGL is holding the winning cards or have merely mastered the art of the bluff. Still, one gets the sense that Hayes has no trouble looking you in the eye when he says, “We're trying to usher in the era of the smart medical device- smarter medical devices... the smartest medical devices.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.